2014
DOI: 10.1177/230949901402200329
|View full text |Cite
|
Sign up to set email alerts
|

Late Recurrence of Osteosarcoma: A Report of Two Cases

Abstract: We report 2 cases of late recurrence of osteosarcoma after 6 and 7 years. One patient had pulmonary metastasis, and the other had soft tissue recurrence. Both patients underwent complete resection and chemotherapy. The first patient achieved complete remission and remained disease-free 47 months later and had no limitation in his daily life. The second patient had a re-recurrence and underwent further resection and chemotherapy. He remained diseasefree 35 months later and could walk using a T-handled walking c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 26 publications
0
4
0
Order By: Relevance
“…[5][6][7] Current treatment of OS, a combination of surgery and chemotherapy (doxorubicin, methotrexate, and cisplatin), has improved outcomes significantly, although this regime is still only successful in 90% of patients. 8 The precise underlying mechanism of OS remains obscure in most individuals; however, the risk of developing OS is influenced by bone turnover, age, environment (drug or radiation therapy), other bone diseases (such as Paget's disease), genetic alterations and hormonal regulation of puberty (such as growth hormone). [9][10][11][12][13] RNA sequencing (RNA-Seq) technology is a powerful tool to analyze the transcriptome of a cell.…”
Section: Introductionmentioning
confidence: 99%
“…[5][6][7] Current treatment of OS, a combination of surgery and chemotherapy (doxorubicin, methotrexate, and cisplatin), has improved outcomes significantly, although this regime is still only successful in 90% of patients. 8 The precise underlying mechanism of OS remains obscure in most individuals; however, the risk of developing OS is influenced by bone turnover, age, environment (drug or radiation therapy), other bone diseases (such as Paget's disease), genetic alterations and hormonal regulation of puberty (such as growth hormone). [9][10][11][12][13] RNA sequencing (RNA-Seq) technology is a powerful tool to analyze the transcriptome of a cell.…”
Section: Introductionmentioning
confidence: 99%
“…The median time to the appearance of HO was shorter than the median time to the appearance of LR (8 months [3][4][5][6][7][8][9][10][11][12][13] versus 16 months [11][12][13][14][15][16][17][18][19][20][21]; p < 0.001). The median time to the initial LR of osteosarcoma was reported to be 14 months in an earlier study [20].…”
Section: Features That Allow the Surgeon To Differentiate Ho From Loc...mentioning
confidence: 99%
“…Hence, the presence or absence of pain may also be useful for differentiating HO from LR. Pain in the affected extremity is the most common symptom of primary or recurrent bone tumors [8,24]. According to the evidence, almost 85% of patients with osteosarcoma and 64% of patients with Ewing sarcoma present with symptoms of pain [24].…”
Section: Features That Allow the Surgeon To Differentiate Ho From Loc...mentioning
confidence: 99%
“…Current treatments of OS include neo-adjuvant chemotherapy with drugs such as doxorubicin, methotrexate, and cisplatin with the aim of reducing tumour size as well as eradicating micro-metastases. Ablative surgery is then followed by further chemotherapy determined by the cell death rate observed in the surgical specimens [7,8]. Current OS therapeutic agents are limited to cytotoxic drugs interfering with transcription and DNA replication [6].…”
Section: Introductionmentioning
confidence: 99%